Quest Diagnostics Aktie
| 152,68USD | -0,29USD | -0,19% |
WKN: 904533 / ISIN: US74834L1008
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,50 |
| The Vanguard Group, Inc. | 12,16 |
| Vanguard Group, Inc. (Subfiler) | 12,06 |
| SSgA Funds Management, Inc. | 4,80 |
| State Street Corp. | 4,72 |
| BlackRock Fund Advisors | 3,45 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 3,31 |
| Vanguard Total Stock Market ETF | 3,14 |
| Victory Capital Management, Inc. (Investment Management) | 3,10 |
| Vanguard 500 Index Fund | 2,64 |
| Geode Capital Management LLC | 2,34 |
| BlackRock Institutional Trust Co. NA | 2,31 |
| Victory Sycamore Established Value Fund | 2,20 |
| Davis Selected Advisers LP | 2,15 |
| Vanguard Mid Cap Index Fund | 2,12 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 47 000 | 49 000 | 49 000 | 49 000 | 48 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,16 | 0,19 | 0,22 | 0,20 | 0,19 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 2 490 | 3 058 | 2 741 | 1 898 | 2 372 |
| Summe Anlagevermögen | 10 353 | 10 968 | 10 870 | 10 939 | 11 650 |
| Summe Aktiva | 12 843 | 14 026 | 13 611 | 12 837 | 14 022 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 7 080 | 7 135 | 7 049 | 6 830 | 7 604 |
| Summe Eigenkapital | 5 763 | 6 891 | 6 562 | 6 007 | 6 418 |
| Summe Passiva | 12 843 | 14 026 | 13 611 | 12 837 | 14 022 |
Adresse
| 500 Plaza Drive, 07940 Secaucus | |
| Telefon | +1 (973) 520-2700 |
| Internet | http://www.questdiagnostics.com |
Management
|
Alyssa Waxenberg
Director-Digital Products & Consumer Marketing |
|
Catherine T. Doherty
Senior Vice President-Regional Businesses |
|
Cecilia K. McKenney
Chief Human Resources Officer & Senior VP |
|
Darren Wheeler
Vice President-Pathology & Medical Services |
|
Denise M. Morrison
Independent Director |
|
Dermot Victor Shorten
Senior Vice President-Ventures, Strategy, M&A |
|
Doug Lang
Director-Technical Products |
|
Gary M. Pfeiffer
Independent Director |
|
James E. Davis
Chairman, President & Chief Executive Officer |
|
Karthik Kuppusamy
Senior Vice President-Clinical Solutions |
|
Kristin Wallace
Chief Compliance Officer & Senior Vice President |
|
Luis A. Diaz
Independent Director |
|
Mark E. Delaney
Chief Commercial Officer & Senior Vice President |
|
Michael E. Prevoznik
Senior Vice President & General Counsel |
|
Michael Joseph Deppe
Chief Accounting Officer, SVP & Controller |
|
Murali Balakumar
Senior VP, Chief Information & Digital Officer |
|
Patrick Plewman
Senior Vice President-Diagnostic Services |
|
Robert B. Carter
Independent Director |
|
Sam A. Samad
Chief Financial Officer & Executive Vice President |
|
Sean D. Mersten
Secretary & Vice President |
|
Shawn Bevec
Vice President-Investor Relations |
|
Timothy L. Main
Independent Director |
|
Timothy M. Ring
Lead Independent Director |
|
Tracey C. Doi
Independent Director |
|
Tracy L. Cinco-Abela
Treasurer & Vice President |
|
Vicky B. Gregg
Independent Director |
|
Wright L. Lassiter
Independent Director |
|
Yuri A. Fesko
Chief Medical Officer & Senior Vice President |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
